Emergent BioSolutions (EBS) PT Raised to $55 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Benchmark Upgrades Emergent BioSolutions (EBS) to Buy
January 20, 2022 6:21 AM ESTBenchmark analyst Robert Wasserman upgraded Emergent BioSolutions (NYSE: EBS) from Neutral to Buy with a price target of $77.00.
For an analyst ratings summary and ratings history on Emergent BioSolutions click here. For more ratings news on Emergent BioSolutions click here.
Shares of Emergent BioSolutions closed at $45.59 yesterday.
... More